TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis.
The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is the rationale for the use of tolebrutinib in MS and what are its advantages over other B-cell directed therapies? (0:13)
- What has the Phase 2b study taught us about the efficacy and safety of tolebrutinib in patients with MS? (1:17)
- Could you tell us a little about the subgroup analysis of patients with highly active relapsing MS? (2:18)
- On the basis of these findings, what will be the likely place of tolebrutinib in the treatment paradigm for MS? (3:27)
Disclosures: Anthony Traboulsee has received research grants from Roche, Sanofi Genzyme, and has personal fees from Biogen, Consortium of MS Centers, Sanofi Genzyme, Roche, Novartis, and Teva Neuroscience.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
